Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Once More, With Statistics: FDA Defends Division Productivity Differences

Executive Summary

Is it a problem that new drugs clear some review divisions faster than others? FDA analysis attributes differences to the proportion of applications qualifying for expedited review – a natural outgrowth of the priority placed on medical advances – not a management problem in need of a fix.

You may also be interested in...

Hematology, Neurology Star In Swan Song For The Office Of New Drugs’ Division Structure

Pink Sheet analysis of three years of novel US FDA approvals show the swiftest average time to approval in oncology, hematology, and antiviral divisions; neurology and hematology divisions contributed the most approvals.

Can US FDA's Talk Therapy Cure What Ails Mental Health R&D?

By reducing regulatory uncertainty, US FDA’s Breakthrough Therapy Designation is helping adventurous sponsors try new trial designs and new mechanism in the long-stagnant field of psychiatry drug development. 

A Pathway, Not A Shortcut: 505(b)(2) NDAs Have Longer Reviews Than NMEs

US FDA's argument that its review resources favor novelty/medical advances could be buttressed by Tufts Center for the Study of Drug Development analysis of (less novel) approvals using the streamlined 505(b)(2) NDA pathway.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts